Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

NCT03172936 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

106

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor's decision

Conditions

Solid Tumors and Lymphomas

Interventions

DRUG: MIW815
BIOLOGICAL: PDR001

Sponsor

Novartis Pharmaceuticals